louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06030700: FoodImage 3 Laboratory
Official title: Multiscale RECIPES (Resilient, Equitable, and Circular Innovations With Partnership and Education Synergies) for Sustainable Food Systems (FoodImage 3; FI3) Laboratory
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Waste Management
Food Supply
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
Collaborators: name: Martin, Corby, K., M.D.
First posted: 2023-09-11
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy Volunteers

Brief summary: The Laboratory Study will be conducted at PBRC and will include participants (N=25) from a wide array of social and economic groups will be recruited and trained on the use of the FoodImage app. Participants use the app to measure food waste (including foods with inedible parts) created during a simulated meal preparation setting, a simulated meal consumption setting with plate waste, and a simulated cabinet and refrigerator clean-out of spoiled and out-of-date foods, where the number of items and the amounts of waste for each task is randomly assigned across participants and blinded from the research staff evaluating images and coding data. These participants will denote the normal discard destination (I.e., garbage, sink/disposal, feed to animal, compost) for each item as if the waste had occurred in their own home.


Eligibility criteria: Inclusion Criteria:

* Male or female, age 18-65 years
* Willing to be recontacted

Exclusion Criteria:

* Refusal or unable to use an iPhone for study related purposes.
* Not willing to adhere to study procedures and study visit timelines.
* PBRC employee
* Any condition or circumstance that in the judgement of the PI could interfere with study participation

Primary outcomes:
measure: Weight of Food Waste
timeFrame: At Baseline Laboratory Study Visit
Secondary outcomes:
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
affiliation: Pennington Biomedical Research Center
name: John W Apolzan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05297500: Determination of SpO2 and PR Accuracy Specifications At Rest (71Ag_Vital-0031)
Official title: Accuracy of Pulse Oximeters with Profound Hypoxia NIHO 14
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Hypoxia
Lead sponsor: Nihon Kohden
Sponsor class: INDUSTRY
Collaborators: name: University of California, San Francisco
First posted: 2022-03-28
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy adult volunteers. At least 10 subjects will be recruited to complete the study. Of these 2 will be dark pigmented. If the number of samples is less than the required 200 or if less than 2 of dark pigment subjects successfully complete the study, subjects will be added to include 2 of dark pigmented subjects and at least 200 data points.

Brief summary: The aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. Study will be used with patients at rest

Detailed description: This study is intended to evaluate performance of a new design pulse oximeter (test device) manufactured by Nihon Kohden Corporation sufficiently to support performance claims for an FDA 510K submission or ISO technical file. Specifically, SpO2 and pulse rate accuracy will be assessed for a Nihon Kohden OLV-4202 pulse oximeter with adult patients under a controlled setting of varying levels of inhaled oxygen concentration levels for patients at rest.

Eligibility criteria: Inclusion Criteria:

* Both male and female subjects who can give written informed consent
* Healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile
* Meeting the demographic requirements

Exclusion Criteria:

* Pregnant women
* Significant arrhythmia
* Blood pressure above 150 systolic or 90 diastolic
* Carboxyhemoglobin levels over 3%
* Subjects whom the investigator consider ineligible for the study

Primary outcomes:
measure: Root-mean-square (Rms) of device SpO2 measurement with room air stabilization is within +-2% [%SpO2] of reference co-oximeter SaO2 measurement at varying desaturation levels (70% to 100%)
timeFrame: 30 minutes
measure: Root-mean-square (Rms) of device Pulse Rate measurement with room air stabilization is within +-3 [1/min] of reference ECG Pulse Rate measurement at heart rates (30 to 300 [1/min])
timeFrame: 30 minutes
Secondary outcomes:
measure: Root-mean-square (Rms) of device SpO2 measurement with room air stabilization is within +-2% [%SpO2] of reference co-oximeter SaO2 measurement at desaturation levels (80% to 100%) and within +-3% [%SpO2] at desaturation levels (70% to 80%)
timeFrame: 30 minutes
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Hypoxia Research Laboratory
state: California
Study officials:
References:
Clinical trial NCT02652000: Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy
Official title: Retrospective Analysis of Quality of Life After Permanent Interstitial Iodine Seed Brachytherapy for Prostate Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neoplasms, Prostate
Lead sponsor: Kantonsspital Graubuenden
Sponsor class: OTHER
Collaborators: name: University of Zurich
First posted: 2016-01-11
Enrollment: 50
Sex: MALE
Minimum age (years): 48
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having had idodine seed brachytherapy for localized prostate cancer between 2009 and 2014

Brief summary: Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer

Detailed description: Retrospective Evaluation of Quality of life data collected on men who underwent iodine seed brachytherapy at the University Hospital Zurich

Eligibility criteria: Inclusion Criteria:

* Male \> 18 years of age
* iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich

Exclusion Criteria:

* No iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich

Primary outcomes:
measure: CTCAE v4.03ff Grade 1-4 Sexual/Reproductive Function
timeFrame: 5 years (2009-2014)
Secondary outcomes:
measure: CTCAE v4.03ff Grade 1-4 Gastrointestinal
timeFrame: 5 years (2009-2014)
measure: CTCAE v4.03ff Grade 1-4 Renal/Genitourinary
timeFrame: 5 years (2009-2014)
measure: International Prostate Symptom Score (IPSS)
timeFrame: 5 years (2009-2014)
measure: International Index of erectile function, five items (IIEF-5)
timeFrame: 5 years (2009-2014)
Other outcomes:
Locations:
city: Chur
country: Switzerland
facility: Kantonsspital Graubuenden, Department of Radiaton Oncology
Study officials:
affiliation: Kantonsspital Graubuenden
name: Daniel R Zwahlen, MD, MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04561700: Nutritive Sucking Patterns in Premature Infants
Official title: Nutritive Sucking Patterns in Premature Infants: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Premature
Light-For-Dates Without Mention of Fetal Malnutrition, Unspecified
Feeding Patterns
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2020-09-24
Enrollment: 0
Sex: ALL
Minimum age (years): 7
Maximum age (years): 60
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In this pilot trial, the investigators will determine the feasibility of monitoring nutritive sucking patterns to facilitate the transition from tube to oral feeding in extremely-low-birth weight (ELBW) infants

Detailed description: In this parallel-group randomized controlled trial, ELBW infants (birthweight \< 1000 grams) will be randomly assigned in a 1:1 ratio to either weekly reporting on objective measurements of sucking activity during oral feeding (intervention group) or usual care without information on sucking activity (control group).

Eligibility criteria: Inclusion Criteria:

* Birthweight \< 1000 grams
* Gestational age \< 32 weeks of gestation
* Full enteral feeding established before or on postnatal day 21
* Oral feeding initiated before or at 33 weeks of postmenstrual age

Exclusion Criteria:

* Major congenital/chromosomal anomalies
* Patent ductus arteriosus causing significant cardiovascular symptoms
* History of necrotizing enterocolitis stage 2 or greater

Primary outcomes:
measure: Time to independent oral feeding
timeFrame: Birth to 120 days
Secondary outcomes:
measure: Postnatal age at discharge
timeFrame: Birth to 120 days
measure: Length of hospital stay
timeFrame: Birth to 120 days
measure: Growth rate during the transition from tube to oral feeding
timeFrame: Birth to 120 days
measure: Tube feeding events per day during the transition from tube to oral feeding.
timeFrame: Birth to 120 days
Other outcomes:
Locations:
Study officials:
affiliation: University of Alabama at Birmingham
name: Ariel A. Salas, MD, MSPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06289400: Magnetic Field Application in Patellofemoral Pain Syndrome
Official title: Investigating the Effect of Magnetic Field Application Used in Patellofemoral Pain Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Knee
Keywords: Pain, Knee, Magnetic field, Physiotherapy
Lead sponsor: KTO Karatay University
Sponsor class: OTHER
First posted: 2024-03-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the effect of magnetic field application used in the treatment of patellofemoral pain.

Detailed description: The aim of this randomized controlled study is to examine the effect of magnetic field application used in the treatment of patellofemoral pain.

The main question it aims to answer is;

Is magnetic field therapy applied in addition to conventional treatment effective in reducing pain in individuals with Patellofemoral pain syndrome?

Eligibility criteria: Inclusion Criteria:

* Having been diagnosed with patellofemoral pain syndrome by an orthopedic physician
* Volunteering to participate in the study
* Having pain for more than eight weeks
* Patients who did not undergo surgery

Exclusion Criteria:

* Patients diagnosed with rheumatological disease
* Patients who have previously had steroid injections in the knee area
* Patients with entrapment neuropathy and deformity in the lower extremity
* Patients who are pregnant
* Patients suffering from scoliosis,
* Patients who use non-steroidal anti-inflammatory and antidepressant regularly for any reason

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: The evaluation will be applied at the beginning of the treatment program.
measure: 36-Item Short Form Survey (SF-36)
timeFrame: The evaluation will be applied at the beginning of the treatment program.
measure: Manual Muscle Test
timeFrame: The evaluation will be applied at the beginning of the treatment program.
measure: The Lower Extremity Functional Scale (LEFS)
timeFrame: The evaluation will be applied at the beginning of the treatment program.
Secondary outcomes:
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: KTO Karatay University
Study officials:
affiliation: KTO Karatay University
name: Osman Karaca, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01228500: The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial
Official title: The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Foot Ulcer, Diabetic
Lead sponsor: Integra LifeSciences Corporation
Sponsor class: INDUSTRY
Collaborators: name: Beth Israel Deaconess Medical Center
First posted: 2010-10-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary aim of this study proposal is to test an innovative form of fetal bovine dermis bioscaffold in combination with negative pressure wound therapy (NPWT) to enhance wound healing in diabetic foot ulcers.


Eligibility criteria: Inclusion Criteria:

* Adult Type 1 or 2 diabetic patients that present with foot ulcers.
* Ulcer size of at least 3 centimeters (cm) in diameter at its widest dimension.
* Ulcer depth: Full thickness (absence of all epithelial layers or deeper)
* Adequate perfusion (at least one palpable pedal pulse or pedal bypass graft)
* All ulcer durations will be eligible
* Patients currently receiving NPWT for a diabetic foot ulcer
* Patients must be appropriate NPWT candidates and be willing and able to sleep, ambulate, and rest with the NPWT unit in place.

Exclusion Criteria:

* Active foot infections
* Presence of any serious disease including end-stage renal failure requiring dialysis or renal transplantation or active malignant disease requiring treatment which seriously compromises the patient's ability to complete this study
* Patients who are pregnant
* Allergies to any material contained within the NPWT or bioscaffold
* Any condition that would exclude NPWT use including but not limited to active bleeding, presence of malignancy in the wound or inability to follow any of the NPWT safety guidelines

Primary outcomes:
measure: Time to healing
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
affiliation: Beth Israel Deaconess Medical Center, Harvard Medical School
name: Jeremy Cook, DPM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04777500: taVNS Treatment for Fibromyalgia
Official title: Applying Transcutaneous Auricular Vagus Nerve Stimulation to Treat Fibromyalgia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Fibromyalgia
Keywords: taVNS
Pain
Neuromodulation
Fibromyalgia
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2021-03-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this research study we want to learn more about if transcutaneous electrical nerve stimulation (TENS), a safe electrical stimulation tool, can relieve Fibromyalgia pain. A total of 60 subjects with Fibromyalgia will be enrolled in this study at Massachusetts General Hospital, Charlestown Navy Yard campus.


Eligibility criteria: Inclusion Criteria:

* Meet the American College of Rheumatology (ACR) 1990 classification criteria and the ACR 2010 diagnostic criteria for fibromyalgia as determined by clinicians.
* Willingness to complete a 4-week, twice-a-day treatments.
* At least a 10th grade English-reading level; English can be a second language provided that the patients understand all questions used in the assessment measures.

Exclusion Criteria:

* Diagnosed with medical conditions that are known to contribute to fibromyalgia symptomatology, such as thyroid disease, inflammatory arthritis, systemic lupus erythematosus, rheumatoid arthritis, myositis, vasculitis, or Sjogren's syndrome.
* History of cardiac, respiratory, or nervous system disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for adverse outcome. For example: asthma or claustrophobia.
* Personal history of medical or psychiatric illness as determined by investigator.
* Pregnant or lactating.
* Less than a 10th grade English-reading level; English can be a second language provided that the patients understand all questions used in the assessment measures.

Primary outcomes:
measure: Revised Fibromyalgia Impact Questionnaire (FIQR)
timeFrame: Baseline, week 2 and week 4.
Secondary outcomes:
measure: Patient Reported Outcomes Measurement Information System (PROMIS-29)
timeFrame: Baseline, week 2 and week 4.
measure: Pain Catastrophizing Scale
timeFrame: Baseline, week 2 and week 4.
measure: Beck Depression Inventory-II (BDI-II)
timeFrame: Baseline and week 4.
measure: Brief Quantitative Sensory Testing (QST)
timeFrame: Baseline and week 4.
measure: Heart rate variability
timeFrame: Baseline and week 4.
measure: power of oscillations in the alpha, theta, and gamma frequencies (optional)
timeFrame: Baseline and week 4.
measure: Blood inflammation markers (optional)
timeFrame: Baseline and week 4
Other outcomes:
Locations:
city: Charlestown
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: MGH
name: Jian Kong
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04200300: Professional Quality of Life in German Mental Health Nursing
Official title: Professional Quality of Life in Nurses Working with Patients with Mental Disorders in Germany
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mental Disorder
Burnout, Professional
Burnout, Caregiver
Keywords: Professional quality of life
Compassion satisfaction
Burnout
Nursing
Mental disorder
Mental health
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2019-12-16
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Nurses that currently work with patients with mental disorders in Germany.

Brief summary: The purpose of this study is to assess professional quality of life in German nurses working with patients with mental disorders.

Detailed description: The purpose of this study is to assess professional quality of life, which includes compassion satisfaction, burnout and secondary traumatization in nurses, working with patients with mental disorders, in Germany.

Eligibility criteria: Inclusion Criteria:

* Nurse
* Currently working with patients with mental disorders
* At least 18 years old
* Sufficient German skills for answering the questionnaire

Exclusion Criteria:

None

Primary outcomes:
measure: Compassion Satisfaction
timeFrame: 1 day
measure: Burnout
timeFrame: 1 day
measure: Secondary Traumatization
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapie - Charité Campus Mitte
Study officials:
affiliation: Charité Universitätsmedizin Berlin- Charité Campus Mitte - Department for Psychiatry and Psychotherapy
name: Moritz B Petzold, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01445600: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
Official title: An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Infections, Bacterial
Keywords: Impetigo
secondarily-infected traumatic lesions
retapamulin
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-10-04
Enrollment: 3612
Sex: ALL
Minimum age (years): 9
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients administrated ALTARGO(retapamulin) with primary impetigo or secondarily infected traumatic lesions in Korea

Brief summary: This is an open label, multi-centre, non-interventional post-marketing surveillance.

Detailed description: This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the prescribing information.

ALTARGO is a trademark of the GlaxoSmithKline group of companies.

Eligibility criteria: Inclusion Criteria:

* All subjects must satisfy the following criteria at study entry:

  1. Subjects administered with ALTARGO(retapamulin) in the topical treatment of the following bacterial skin and skin structure infections (SSSI)
  2. Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen
  3. Subjects administered with ALTARGO(retapamulin) following the locally approved prescribing information

Exclusion Criteria:

* Considering the nature of observational study, GSK Korea encourages the doctors participating in this study to enrol the subjects prescribed with retapamulin following the locally approved Prescribing Information.

  1. Subjects with a known or suspected hypersensitivity to ALTARGO(retapamulin) or any component of the ointment
  2. Infants under nine months of age

Primary outcomes:
measure: The number of adverse event after ALTARGO(retapamulin) treatment
timeFrame: 14 days
Secondary outcomes:
measure: The number of unexpected adverse event after ALTARGO(retapamulin) treatment
timeFrame: 14 days
measure: The number of serious adverse event after ALTARGO(retapamulin) treatment
timeFrame: 14 days
measure: Effectiveness of ALTARGO(retapamulin) treatment
timeFrame: 7 days
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: